Role of Dexmedetomidine in Spinal and Epidural Procedures

Mechanism of Action and Benefits

Dexmedetomidine is an α2-adrenoreceptor agonist that inhibits neuronal activity in the brain and spinal cord, producing sedative, analgesic, anxiolytic, and sympatholytic effects 1, 2
Unlike other sedatives, patients receiving dexmedetomidine can return to baseline consciousness when stimulated, making it unique among sedative agents 1
It produces less respiratory depression compared to other sedative agents, which is a significant advantage in procedural sedation 2
Its pharmacologic effects can be reversed by the α2-receptor antagonist atipamezole 1

For procedural sedation, the usual dose is 1 μg/kg followed by an infusion of 0.2 μg/kg/h 1
Onset of action is less than 5 minutes with peak effect occurring within 15 minutes 1

Dexmedetomidine has a biphasic cardiovascular effect, with an initial transient increase in blood pressure due to peripheral α-adrenoreceptor stimulation, followed by a 10-20% decrease in blood pressure within 5-10 minutes due to central sympathetic inhibition 2
Common cardiovascular side effects include bradycardia (reported in 10% of patients in some studies) 1 and hypotension (reported in 21% of patients in some studies) 1
Arrhythmias including sinus bradycardia, AV block, and sinus arrest may occur 3
Should be used with caution in patients with severe cardiac disease, conduction disorders, or rhythm abnormalities 3

Intraoperative use of dexmedetomidine in video-assisted thoracoscopic surgery (VATS) has been shown to reduce pain scores and opioid demand, decrease postoperative agitation and cognitive dysfunction, reduce postoperative nausea and vomiting, and improve lung function with increased FEV1 and vital capacity 3
In total hip arthroplasty, dexmedetomidine as part of the anesthetic protocol showed small but significant pain reduction and lower risk of delirium compared to propofol when used as a sedative with regional anesthesia 4

Bradycardia is reported as a significant and frequent side effect, particularly when used in orthopedic procedures 4
Other common side effects include vertigo (reported in 26% of patients in some studies) 1 and sedation (which may be beneficial or undesirable depending on the clinical context) 3
Postoperative IV dexmedetomidine is not recommended due to conflicting evidence and potential for serious complications without proper monitoring 3
Dexmedetomidine in combination with fentanyl-based intravenous PCA has shown comparable analgesic effects to patient-controlled epidural analgesia but with less hemodynamic instability 5

The European Society for Paediatric Anaesthesiology recommends a bolus dose of 0.5-1 mcg/kg IV for pediatric patients undergoing surgery, as part of multimodal analgesia to reduce opioid requirements and improve postoperative pain control 6, 7, 8
Alternative higher-range dosing of 1-3 mcg/kg IV bolus can be used for more intensive analgesia requirements in pediatric patients 6, 7
Maintenance infusion of 0.2-0.7 mcg/kg/h until the end of the procedure is recommended for pediatric patients 6, 7, 8

No relevant facts with citations are available for cardiovascular response and monitoring.

No relevant facts with citations are available for contraindications to bolus dosing.

No relevant facts with citations are available for key advantages over other sedatives.